Vivos Therapeutics Inc. VVOS Archives - Page 2 of 4

WednesdaySep 08, 2021 12:04 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”) and snoring, today announced its participation at the H.C. Wainwright 23rd Annual Global Investment Conference. Vivos CEO Kirk Huntsman will be presenting at the event beginning at 7:00 a.m. EDT on Monday, Sept. 13, 2021. Interested institutional or retail investors should visit https://ibn.fm/VL1jk to register for the conference and may listen to the company’s presentation online at https://ibn.fm/YuFWj. A replay of the presentation will be available via the Investor Relations page of the company’s website. To…

ThursdayAug 26, 2021 12:28 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Partners with Empower Sleep in Effort to Improve OSA Diagnosis, Treatment

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), is teaming up with Empower Sleep. Vivos and the California-based company, which works to empowering patients with affordable, accessible and personalized telemedicine sleep care, are partnering to offer key diagnostic and medical consultation services to people across North America who suffer from OSA. The partnership will combine core technologies from each company to develop an accessible platform for patients being screened for OSA; the solution will be available throughout North…

MondayAug 23, 2021 10:07 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Receives FDA Clearance for mmRNA Oral Appliance

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has received 510(k) market clearance from the FDA for its modified mandibular repositioning nighttime appliance (“mmRNA”). The device is designed to treat mild-to-moderate OSA in adults; it is also used for treating sleep-disordered breathing and snoring. The FDA approval expands insurance reimbursement potential, including the potential for the device to be covered by Medicare. The FDA approval also opens the door for future government contracts and other commercial payers. According…

WednesdayAug 18, 2021 9:45 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in the study who used Vivos’ FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; that is officially defined as patients in post treatment having an Apnea Hypopnea Index (“AHI”) score of less than 5. According to the announcement, before the…

FridayAug 13, 2021 9:39 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report noted that second-quarter revenue totaled $4.5 million, an increase of more than 37% year over year, and 30% over the first quarter 2021; revenue for the first half of 2021 totaled $7.9 million. Gross profit for second quarter was $3.6 million with gross margin 81%…

TuesdayAug 10, 2021 10:10 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Participation in Q3 Virtual Investor Summit

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), will participate in the upcoming two-day Q3 Virtual Investor Summit. Vivos CEO Kirk Huntsman along with CFO Brad Amman and Ed Loew, Vivos investor relations officer, will be presenting at the event, which will be held Aug. 17–18; their presentation is slated to begin at 9:30 a.m. ET on Aug. 18, 2021. The Vivos presentation will be available online, and a replay of the presentation will be available to view…

MondayAug 09, 2021 11:17 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Conference Call to Discuss Q2 2021 Financial Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has scheduled a conference call and live webcast for Aug. 12, 2021, to begin at 5 p.m. ET. The purpose of the call is to discuss the company’s second-quarter financial results, which Vivos plans to release after market close on the same day. The call will also include an overview of the company’s recent milestones and growth strategy. Those interested may access the call by dialing (888) 204-4368; international callers…

ThursdayJul 29, 2021 12:26 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced that it has opened the Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility was established to provide advanced post-graduate education and training to dentists, dental teams and other health care providers in a live and hands-on setting. The Institute’s emphasis will focus on educating health care providers about OSA, Vivos’ treatments for OSA within their practice areas and providing training on Vivos’ related practice management tools…

TuesdayJul 13, 2021 11:47 am

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, defined as patients having an Apnea Hypopnea Index (“AHI”) score of less than five post-treatment. “We are not aware of any treatment for…

WednesdayJul 07, 2021 1:39 pm

QualityStocksNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that 63% of patients reported that they depend on their dentist’s advice as they look for lasting solutions that addresses the root cause of their OSA and 29% indicated they searched for nonsurgical alternatives to current…

Site Search

Company Search

Tag: Vivos Therapeutics Inc. VVOS